Teknova Inc (TKNO) - התחייבויות לטווח ארוך להון

Alpha Teknova, Inc. (TKNO) minimizes risks by producing culture media and reagents for gene therapy and vaccines, ensuring sustainable sales. The business leverages significant pricing power through the rapid manufacturing of customized GMP solutions. The current metric stands at 0.42. This price chart is supplemented by data on the implementation of AI systems in the automation of biopharmaceutical filling and dosing.

To objectively assess the operational resilience of Alpha Teknova, Inc. (TKNO), investors must understand the company's degree of reliance on borrowed funds for asset financing. By analyzing the long-term debt-to-equity ratio, we compare liabilities with maturities exceeding one year against shareholders' equity, which allows for an evaluation of the issuer's financial cushion amid geopolitical instability and rising costs for chemical reagent supplies.